Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?

Current Opinion in Rheumatology

Volumn 31, Issue 3, 2019, Pages 285-292

  Jani, Meghna ^a,d   Barton, Anne ^b,c   Hyrich, Kimme ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

anti tumour necrosis factor; biologics; infection; rheumatoid arthritis; stratification

Indexed keywords

BIOLOGICAL PRODUCT; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; NARCOTIC ANALGESIC AGENT; PHARMACOLOGICAL BIOMARKER; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; ETANERCEPT;

DEMOGRAPHY; HUMAN; INFECTION; INFECTION RISK; OPPORTUNISTIC INFECTION; PREDICTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; DIAGNOSIS; RISK ASSESSMENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; ETANERCEPT; HUMANS; INFECTIONS; RISK ASSESSMENT;

EID: 85063962633     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000598     Document Type: Review

References (47)

1. Hazlewood GS, Bombardier C, Tomlinson G, et al. Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment. Rheumatology 2016; 55:1959-1968.
2. Subesinghe S, Rutherford AI, Ibrahim F, et al. A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord 2016; 17:322.
3. Jinno S, Lu N, Jafarzadeh SR, et al. Trends in hospitalizations for serious infections in patients with rheumatoid arthritis in the US between 1993 and 2013. Arthritis Care Res (Hoboken) 2018; 70:652-658.
4. Walkey AJ, Lagu T, Lindenauer PK. Trends in sepsis and infection sources in the United States. A population-based study. Ann Am Thorac Soc 2015; 12:216-220.
5. Askling J, Dixon W. The safety of antitumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20:138-144.
6. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special EMPH. Rheumatology (Oxford) 2011; 50:124-131.
7. Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015; 386:258-265.
8. Sharma C, Keen H. Ten-year retrospective review of the incidence of serious infections in patients on biologic disease modifying agents for rheumatoid arthritis in three tertiary hospitals in Western Australia. Intern Med J 2018; doi: 10.1111/imj.14109. [Epub ahead of print]
9. Rutherford AI, Patarata E, Subesinghe S, et al. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology 2018; 57:997-1001.
10. Leon L, Gomez A, Vadillo C, et al. Severe adverse drug reactions to biological disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 2018; 36:29-35.
11. Cobo-Ibánẽz T, Descalzo MÁ, Loza-Santamara E, et al. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatol Int 2014; 34:953-961.
12. Jani M, Hirani N, Matteson EL, et al. The safety of biologic therapies in RAassociated interstitial lung disease. Nat Rev Rheumatol 2014; 10:284-294.
13. Rutherford AI, Subesinghe S, Hyrich KL, et al. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2018; 77:905-910.
14. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69:522-528.
15. Winthrop KL, Weinblatt ME, Daley CL. You can't always get what you want, but if you try sometimes (with two tests-TST and IGRA-for tuberculosis) you get what you need. Ann Rheum Dis 2012; 71:1757-1760.
16. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; (2):CD008794.
17. Solomon DH, Shadick NA, Weinblatt ME, et al. Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement. Arthritis Res Ther 2017; 19:130.
18. Silva-Fernández L, De Cock D, Lunt M, et al. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology 2018; 57:1533-1540.
19. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet (London, England) 2013; 381:1541-1550.
20. Jani M, Dixon WG, Kearsley-Fleet L, et al. Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open 2017; 3:e000314.
21. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic diseasemodifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59:1074-1081.
22. Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012; 71:1128-1133.
23. Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care Res 2017; 69:1111-1124.
24. George MD, Baker JF, Hsu JY, et al. Perioperative timing of infliximab and the risk of serious infection after elective hip and knee arthroplasty. Arthritis Care Res (Hoboken) 2017; 69:1845-1854.
25. Curtis JR, Xie F, Smith C, et al. Changing trends in opioid use among patients with rheumatoid arthritis in the United States. Arthritis Rheumatol 2017; 25:553-559.
26. Plein LM, Rittner HL. Opioids and the immune system: friend or foe. Br J Pharmacol 2018; 175:2717-2725.
27. Wiese AD, Griffin MR, Stein CM, et al. Opioid analgesics and the risk of serious infections among patients with rheumatoid arthritis: a self-controlled case series study. Arthritis Rheum 2016; 68:323-331.
28. Dublin S, Von Korff M. Prescription opioids and infection risk: research and caution needed. Ann Intern Med 2018; 168:444.
29. Wiese AD, Griffin MR, Schaffner W, et al. Opioid analgesic use and risk for invasive pneumococcal diseases. Ann Intern Med 2018; 168:396.
30. Robinson DE, van Staa TP, Dennison EM, et al. The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: a cohort study. Bone 2018; 117:83-90.
31. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50:1412-1419.
32. Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-765.
33. Lau AN, Wong-Pack M, Rodjanapiches R, et al. Occurrence of serious infection in patients with rheumatoid arthritis treated with biologics and denosumab observed in a clinical setting. J Rheumatol 2018; 45:170-176.
34. Curtis JR, Xie F, Yun H, et al. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis Rheumatol 2015; 67:1456-1464.
35. Hoffmann TC, Del Mar C. Clinicians' expectations of the benefits and harms of treatments, screening, and tests. JAMA Intern Med 2017; 177:407.
36. Subesinghe S, Rutherford AI, Byng-Maddick R, et al. Biologic prescribing decisions following serious infection: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology 2018; 57:2096-2100.
37. Crowson CS, Hoganson DD, Fitz-Gibbon PD, et al. Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64:2847-2855.
38. Curtis JR, Xie F, Chen L, et al. Use of a disease risk score to compare serious infections associated with antitumor necrosis factor therapy among highversus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2012; 64:1480-1489.
39. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70:1914-1920.
40. Curtis JR,Winthrop K, O'Brien C, et al. Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment. Arthritis Res Ther 2017; 19:276.
41. Zink A, Manger B, Kaufmann J, et al. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis 2014; 73:1673-1676.
42. RABBIT risk score calculator. http://www.biologika-register.de/en/home/riskscore/. [Accessed 5 December 2018]
43. Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-TNF drug level testing and measurement of antidrug antibodies on long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol 2015; 67:2011-2019.
44. Jani M, Isaacs JD, Morgan AW, et al. High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegoltreated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann Rheum Dis 2017; 76:208-213.
45. Vogelzang EH, Hebing RC, Nurmohamed MT, et al. Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up. PLoS One 2018; 13:e0205125.
46. Jani M, Dixon WG, Lunt M, et al. The association of biologic drug-levels with infection risk: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2018; 77:A163.
47. L'ami MJ, Krieckaert CLM, Nurmohamed MT, et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: An open-label, noninferiority, randomised clinical trial. Ann Rheum Dis 2018; 77:484-487.